← Eichor
Study identifier: NCT02622581 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Condition: Metastatic Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer Metastatic · Non-small Cell Lung Cancer Stage II  ·  Sponsor: AIO-Studien-gGmbH

PhaseN/A
Planned participants12400
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany

This description comes directly from the study's public registry record.

Talk to the study team

Annika Groth  ·  +49 30-8145344-39  ·  annika.groth@aio-studien-ggmb.de

Paula Ludwig  ·  +49 30-8145344-63  ·  Paula.Ludwig@aio-studien-ggmbh.de

Always discuss trial participation with your own doctor first.

Locations (1)

Pius-HospitalOldenburg, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02622581